HOME Top Market Reports Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020

Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020

By: marketsandmarkets.com
Publishing Date: November 2015
Report Code: PH 3926

Discount on Reports  

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The immunotherapy drugs market is estimated to grow at a CAGR of 12.8% to reach USD 73,529.2 Million by 2020. The checkpoint inhibitors, by type of drugs, are expected to witness the fastest growth during the forecast period.

In this report, the immunotherapy market is segmented into types of drugs and region. By types of drug, the market is further subsegmented into antibodies, interferons, interleukins, vaccines and checkpoint inhibitors.

One of the most recent discoveries, the checkpoint inhibitors are expected to grow at highest rate during the forecast period among all the segments of cancer immunotherapy drugs. The growth of the segment is owing to the technological advancements and high efficacy.

By region, the immunotherapy drugs market is segmented into North America, Europe, Asia-Pacific and Rest of the World. (RoW). The North American geographic segment is expected to account for the largest share of this market, followed by Europe in 2015.

The major drivers for the growth of immunotherapy drugs market are increasing incidence of different types of cancer; focus on targeted therapies with fewer side effects and quicker drug approval processes. On the other hand, the high cost of novel cancer therapies and limited knowledge of cancer immunobiology are the major factors hindering the growth of immunotherapy drugs market.

Key players in the immunotherapy drugs market include Amgen Inc. (U.S.), GlaxoSmithKline Plc. (U.K.), Merck & Co., Inc. (U.S.), Novartis International Ag (Switzerland),and Roche Holding Ag (Switzerland).

Scope of the Report

Particular

Scope

Historical Years

2013

Base Year

2014

Estimated Year

2015

Projected Year

2020

Forecast Period

20152020

Revenue Currency

USD ($)

Market Segmentation

Immunotherapy drugs market is categorized into different segments namely by, types of drugs and region. These segments are further categorized into subsegment and they are as follows.

  1. Immunotherapy Drugs Market, by Types
    • Antibodies
    • Interferons
    • Interleukins
    • Vaccines
    • Checkpoint Inhibitors
  2. Immunotherapy Drugs Market, by Region
    • North America
      • The U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
    • Asia-Pacific
      • Japan
      • China
      • India
    • Rest of the World

Table of Contents

1 Introduction (Page No. - 13)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 16)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
           2.2.1 Key Data From Secondary Sources
           2.2.2 Key Data From Primary Sources
                    2.2.2.1 Key Industry Insights
           2.2.3 Assumptions for the Study

3 Executive Summary (Page No. - 23)

4 Premium Insights (Page No. - 26)
    4.1 Immunotherapy Drugs Market to Grow at A Rapid Rate
    4.2 Global Immunotherapy Drugs Market Size
    4.3 Geographical Snapshot of the Immunotherapy Drugs Market
    4.4 Immunotherapy Drugs Market, By Type of Drug
    4.5 Lifecycle Analysis, By Region

5 Market Overview (Page No. - 30)
    5.1 Introduction
    5.2 Market Segmentation
    5.3 Market Dynamics
    5.4 Drivers
           5.4.1 Increasing Adoption of Targeted Therapy Over Traditional Therapy
           5.4.2 Reduction in Overall Timeline and Cost for Drug Discovery
           5.4.3 High Prevalence Rate of Lifestyle Diseases
           5.4.4 Fast Track and Orphan Drug Designations
    5.5 Restraints
           5.5.1 High Cost of Immunotherapy Treatment
           5.5.2 High Attrition Rate in the Product Development Cycle
    5.6 Opportunities
           5.6.1 Significant Growth Prospects in Developing Countries
           5.6.2 Immunotherapy to Replace Chemotherapy as A First-Line Therapy
    5.7 Challenges
           5.7.1 Patent Expiries of Top-Selling Biologics

6  Cancer Immunotherapy Market- Industry Insights (Page No. - 36)
    6.1 Cancer Epidemiology
           6.1.1 Estimated Incidence, Mortality, and 5-Year Prevalence: Men (2012)
           6.1.2 Estimated Incidence, Mortality, and 5-Year Prevalence: Women
           6.1.3 Estimated Incidence, Mortality, and 5-Year Prevalence: Both Sexes (2012)
    6.2 Pricing and Reimbursement
           6.2.1 U.S.
           6.2.2 U.K.
           6.2.3 France
           6.2.4 Germany
           6.2.5 Other European Countries
           6.2.6 Japan
    6.3 Pipeline
           6.3.1 Phase 1
           6.3.2 Phase I/II
           6.3.3 Phase II
           6.3.4 Phase II/III
           6.3.5 Phase III
           6.3.6 Application Submitted
    6.4 Promising Molecules
    6.5 Treatment Protocols and Line of Therapies
           6.5.1 First Line Therapy
           6.5.2 Second Line Therapy
           6.5.3 Other Treatments

7 Immunotherapy Drugs Market, By Type of Drugs (Page No. - 63)
    7.1 Introduction
    7.2 Monoclonal Antibodies
    7.3 Interferons
    7.4 Interleukins
    7.5 Vaccines
    7.6 Checkpoint Inhibitors

8 Global Immunotherapy Drugs Market, By Region (Page No. - 76)
    8.1 Introduction
    8.2 North America
           8.2.1 U.S.
           8.2.2 Canada
    8.3 Europe
           8.3.1 Germany
           8.3.2 U.K.
           8.3.3 France
           8.3.4 Italy
           8.3.5 Spain
    8.4 Asia-Pacific
           8.4.1 Japan
           8.4.2 China
           8.4.3 India
    8.5 Rest of the World (RoW)

9 Competitive Landscape (Page No. - 94)
    9.1 Overview
    9.2 Market Share Analysis
    9.3 Competitive Situation and Trends
           9.3.1 Approvals
           9.3.2 Agreements, Partnerships, and Collaborations
           9.3.3 Acqusitions

10 Company Profiles (Page No. - 100)
     10.1 Introduction
     10.2 F. Hoffmann-La Roche Ag
           10.2.1 Business Overview
           10.2.2 F. Hoffmann-La Roche Ag: Company Snapshot
           10.2.3 Products Offered
           10.2.4 Recent Developments
           10.2.5 MnM View
     10.3 Merck & Co., Inc.
           10.3.1 Business Overview
           10.3.2 Merck & Co., Inc.: Company Snapshot
           10.3.3 Products Offered
           10.3.4 Recent Developmen
           10.3.5 MnM View
     10.4 Novartis International Ag
           10.4.1 Business Overview
           10.4.2 Novartis International Ag: Company Snapshot
           10.4.3 Products Offered
           10.4.4 Recent Developments
           10.4.5 MnM View
     10.5 Glaxosmithkline Plc
           10.5.1 Business Overview
           10.5.2 Glaxosmithkline Plc: Company Snapshot
           10.5.3 Product Offered
           10.5.4 Recent Developments
           10.5.5 MnM View
     10.6 Amgen Inc.
           10.6.1 Business Overview
           10.6.2 Amgen Inc.: Company Snapshot
           10.6.3 Products Offered
           10.6.4 Recent Developments
           10.6.5 MnM View
     10.7 Bristol-Myers Squibb
           10.7.1 Business Overview
           10.7.2 Bristol-Myers Squibb: Company Snapshot
           10.7.3 Products Offered
           10.7.4 Recent Developments
     10.8 ELI Lilly and Company
           10.8.1 Business Overview
           10.8.2 ELI Lilly and Company: Company Snapshot
           10.8.3 Product Offered
           10.8.4 Recent Developments
     10.9 Celgene Corporation
           10.9.1 Business Overview
           10.9.2 Celgene Corporation: Company Snapshot
           10.9.3 Products Offered
           10.9.4 Recent Development
     10.10 Seattle Genetics, Inc.
           10.10.1 Business Overview
           10.10.2 Seattle Genetics, Inc.: Company Snapshot
           10.10.3 Product Offered
           10.10.4 Recent Developments
     10.11 Spectrum Pharmaceuticals, Inc.
           10.11.1 Business Overview
           10.11.2 Spectrum Phrmaceuticals, Inc.: Company Snapshot
           10.11.3 Product Offered
           10.11.4 Recent Developments

11 Appendix (Page No. - 121)
     11.1 Insights of Industry Experts
     11.2 Discussion Guide
     11.3 Introducing RT: Real-Time Market Intelligence
     11.4 Available Customizations
     11.5 Related Reports


List of Tables (37 Tables)

Table 1 Global Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 2 Global Monoclonal Antibody Drugs Market Size, By Region,  2013-2020 (USD Million)
Table 3 North America: Monoclonal Antibody Drugs Market Size, By Country,  2013-2020 (USD Million)
Table 4 Europe: Monoclonal Antibody Drugs Market Size, By Country,  2013-2020 (USD Million)
Table 5 Asia-Pacific: Monoclonal Antibody Drugs Market Size, By Country,  2013-2020 (USD Million)
Table 6 Global Interferon Drugs Market Size, By Region, 2013-2020 (USD Million)
Table 7 North America: Interferon Drugs Market Size, By Country,  2013-2020 (USD Million)
Table 8 Europe: Interferon Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 9 Asia-Pacific: Interferon Drugs Market Size, By Country,  2013-2020 (USD Million)
Table 10 Global Interleukin Drugs Market Size, 2013-2020 (USD Million)
Table 11 Global Vaccines Market Size, By Region, 2013-2020 (USD Million)
Table 12 Global Vaccines Market Size, By Type, 2013-2020 (USD Million)
Table 13 North America: Vaccines Market Size, By Country, 2013-2020 (USD Million)
Table 14 Europe: Vaccines Market Size, By Country, 2013-2020 (USD Million)
Table 15 Asia-Pacific: Vaccines Market Size, By Country, 2013-2020 (USD Million)
Table 16 Global Checkpoint Inhibitor Drugs Market Size, By Region,  2013-2020 (USD Million)
Table 17 North America: Checkpoint Inhibitor Drugs Market Size, By Country,  2013-2020 (USD Million)
Table 18 Europe: Checkpoint Inhibitor Drugs Market Size, By Country,  2013-2020 (USD Million)
Table 19 Asia-Pacific: Checkpoint Inhibitor Drugs Market Size, By Country,  2013-2020 (USD Million)
Table 20 Global Immunotherapy Drugs Market Size, By Region,  20132020 (USD Million)
Table 21 North America: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 22 U.S.: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 23 Canada: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 24 Europe: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 25 Germany: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 26 U.K.: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 27 France: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 28 Italy: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 29 Spain: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 30 APAC: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 31 Japan: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 32 China: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 33 India: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 34 RoW: Immunotherapy Drugs Market Size, By Type of Drug,  20132020 (USD Million)
Table 35 Approvals, 20132015
Table 36 Agreements, Partnerships, and Collaborations, 20132015
Table 37 Acqusitions, 2013-2015


List of Figures (29 Figures)

Figure 1 Research Design: Immunotherapy Drugs Market
Figure 2 Market Size Estimation
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Data Triangulation Methodology
Figure 5 Immunotherapy Drugs Market Snapshot (2015 vs 2020): Checkpoint Inhibitors Will Grow at the Highest Rate in the Next Five Years
Figure 6 Global Immunotherapy Drugs Market, By Type of Drug, 2015
Figure 7 Global Immunotherapy Drugs Market Share, 2015
Figure 8 Changing Demograhics and Focus on Targeted Therapies to Drive Market Growth
Figure 9 Monoclonal Antibodies to Account for the Largest Share of the Market in 2015
Figure 10 APAC to Grow at the Highest Rate During the Forecast Period
Figure 11 Checkpoint Inhibitors Expected to Be the Fastest Growing Segment
Figure 12 North America and APAC Markets Hold Lucrative Growth Opportunities
Figure 13 Market Segmentation
Figure 14 Global Immunotherapy Drugs Market: Drivers, Restraints, Opportunities & Challenges
Figure 15 Monoclonal Antibodies Segment is Expected to Dominate the Market in 2015
Figure 16 Interferon Drugs Market in APAC to Witness Highest Growth From 2015 to 2020
Figure 17 Therapeutic Vaccines to Witness Higher Growth in the Forecast Period
Figure 18 North America to Witness Highest Growth in the Checkpoint Inhibitors Market From 2015 to 2020
Figure 19 Geographic Snapshot (2015): Asia-Pacific Will Be the Fastest-Growing Region By 2020
Figure 20 North America, an Attractive Destination for Monoclonal Antibodies and Checkpoint Inhibitors
Figure 21 North America: Immunotherapy Drugs Market Snapshot
Figure 22 The Checkpoint Inhibitors Segment is the Fastest-Growing Market Segment in the U.S.
Figure 23 The Monoclonal Antibodies Segment to Dominate the Immunotherapy Drugs Market in Europe During the Forecast Period
Figure 24 APAC: Immunotherapy Drugs Market Snapshot
Figure 25 The Increasing Number of Key Market Players Focusing on Latin American Countries is Driving the Immunotherapy Drugs Market in the RoW Region
Figure 26 Companies Adopted New Product Launches and Approvals as Their Key Growth Strategy Over the Last Three Years
Figure 27 Global Immunotherapy Drugs Market Share Analysis, By Key Player, 2014
Figure 28 Battle for Market Share: Approvals Was the Key Growth Strategy Adopted By Market Players From 2013 to 2015
Figure 29 Geographic Revenue Mix of the Top Four Market Players

The immunotherapy drugs market is expected to grow at a CAGR of 12.8% to reach USD 73,529.2 Million by 2020. The growing focus on cancer therapies with fewer side effects is a key factor driving the growth of the global immunotherapy drugs market. Other factors driving the market include high prevalence rate of lifestyle diseases including cancer, fast track and orphan drug designations expediting the review of drugs. Factors such as high costs of treatment and lesser number of products getting approved are expected to restrict market growth. On the other hand significant growth prospects in the developing economies and high potential of immunotherapy to get approved as first line treatment are the major opportunities in the market.

The immunotherapy drugs market is broadly segmented on the basis of type of drug and geography. The major types of drugs considered include monoclonal antibodies, interferons alpha, interleukins, and vaccines. Among these drugs, monoclonal antibodies are expected to command the largest share while checkpoint Inhibitors is expected to grow at the fastest rate. Both categories of drugs are targeted therapies which act upon the targets that cannot be captured by small-molecule drugs and precisely identify and attack diseased cells, while doing little damage to normal cells.

On the basis of region, the immunotherapy drugs market is segmented into North America, Europe, Asia-Pacific and Rest of the World. (RoW). The North American geographic segment is expected to account for the largest share of immunotherapy drugs market, followed by Europe in 2015. Cancer is one of the highest funded topics of research in North America due to which this segment has gained special focus for research of cancer immunotherapy. Other driving factors include quicker drug approvals by Food and Drug Administration (FDA) and growth in population as well as aging of the population which are also responsible for rapid growth of the immunotherapy drugs market in North America.

Major players operating in the immunotherapy drugs market are Amgen Inc. (U.S.), GlaxoSmithKline Plc. (U.K.), Merck & Co., Inc. (U.S.), Novartis International Ag (Switzerland),and Roche Holding Ag (Switzerland).

Immunotherapy Drugs Market

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Pharmaceuticals Markets on KnowledgeStore
Request Demo